THE TYPE-III PHOSPHODIESTERASE INHIBITOR MILRINONE AND TYPE-V PDE INHIBITOR DIPYRIDAMOLE INDIVIDUALLY AND SYNERGISTICALLY REDUCE ELEVATED PULMONARY VASCULAR-RESISTANCE

The effects of the phosphodiesterase (PDE) inhibitors milrinone and dipyridamole were studied in an in situ perfused rabbit lung model in which the pulmonary vascular resistance (PVR) was elevated by infusion of the thromboxane-A2 mimetic U46619. Dose-response curves for reduction of elevated PVR were generated for each of these drugs. The EC50 for milrinone was approximately 2 μM. The EC50 for dipyridamole was approximately 0.2 μM. In separate experiments, 0.1 μM milrinone was found to reduce elevated PVR by 4.6 ± 2.4%, 0.06 μM dipyridamole reduced elevated PVR by 8.2 ± 2.8%, whereas the combination of 0.1 μM milrinone and 0.06 μM dipyridamole reduced elevated PVR by 41.9 ± 7.3%. In more limited experiments, it was determined that the PDE type V inhibitor zaprinast also caused a synergistic reduction of PVR when used with milrinone. We concluded that both the type III PDE inhibitor milrinone and the type V PDE inhibitors dipyridamole or zaprinast are effectively able to reduce elevated PVR and that the combination of PDE type III and type V inhibitors is synergistic in the ability to reduce elevated PVR. We speculate that type V PDE may play a more important role than type III PDE in the regulation of pulmonary vascular tone. It is proposed that the combination of milrinone and dipyridamole has the potential to be useful in the clinical treatment of elevated PVR. © 1994 Academic Press. All rights reserved.